Open AccessNasal Shedding of Equine Herpesvirus‐1 from Horses in an Outbreak of Equine Herpes Myeloencephalopathy in W estern C anada
Author(s) -
Burgess B.A.,
Tokateloff N.,
Manning S.,
Lohmann K.,
Lunn D.P.,
Hussey S.B.,
Morley P.S.
Publication year - 2012
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2012.00885.x
Subject(s) - medicine , outbreak , biosecurity , horse , viral shedding , equine herpesvirus 1 , veterinary medicine , nasal discharge , disease , odds ratio , virology , virus , surgery , viral disease , pathology , biology , herpesviridae , paleontology
Background There is little information on the duration of nasal shedding of EHV ‐1 from horses with naturally occurring equine herpesvirus myeloencephalopathy ( EHM ). Objectives To evaluate the duration of nasal shedding of EHV ‐1 in horses affected by EHM. Animals One hundred and four horses naturally exposed to EHV ‐1, 20 of which had clinical signs of EHM . Methods All horses on affected premises were monitored. Those horses developing EHM were sampled in a longitudinal outbreak investigation. Nasal swabs were collected daily from 16 of 20 horses affected by EHM . A qPCR was performed on 98 of 246 nasal swab samples to determine nasal shedding duration. Historical and clinical information was analyzed to evaluate potential risk factors for developing EHM and duration of shedding during this outbreak. Results The last day shedding was detected in any horse was Disease Day 9. EHV ‐1 was detected in two‐thirds of horses tested on Disease Days 0–3. The amount of EHV ‐1 DNA found in nasal swabs varied markedly and was not associated with disease severity or age. The odds of developing EHM were greater for febrile horses ( OR = 20.3; 95% CI 3.4–390.3; P = .01) as well as for horses attending the riding clinic ( OR = 4.1; 95% CI 0.84–21.65; P = .08). Conclusions and Clinical Importance Biosecurity measures should be implemented for a minimum of 14 days beyond the onset of clinical signs of EHM . Animal managers cannot rely on the severity of clinical signs to predict the duration of EHV ‐1 shedding.